Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Corteva Inc (CTVA)

Corteva Inc (CTVA)
62.25 x 2 63.83 x 57
Post-market by (Cboe BZX)
62.76 -1.07 (-1.68%) 02/21/25 [NYSE]
62.25 x 2 63.83 x 57
Post-market 61.93 -0.83 (-1.32%) 17:46 ET
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
62.54
Day High
63.73
Open 63.64
Previous Close 63.83 63.83
Volume 2,476,700 2,476,700
Avg Vol 4,067,695 4,067,695
Stochastic %K 47.87% 47.87%
Weighted Alpha +16.58 +16.58
5-Day Change -0.10 (-0.16%) -0.10 (-0.16%)
52-Week Range 50.01 - 66.24 50.01 - 66.24
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 43,025,496
  • Shares Outstanding, K 685,556
  • Annual Sales, $ 16,908 M
  • Annual Income, $ 907,000 K
  • EBIT $ 2,193 M
  • EBITDA $ 3,420 M
  • 60-Month Beta 0.78
  • Price/Sales 2.59
  • Price/Cash Flow 14.55
  • Price/Book 1.83

Options Overview Details

View History
  • Implied Volatility 27.38% ( +2.83%)
  • Historical Volatility 24.78%
  • IV Percentile 59%
  • IV Rank 60.39%
  • IV High 36.75% on 05/01/24
  • IV Low 13.10% on 03/20/24
  • Put/Call Vol Ratio 1.01
  • Today's Volume 813
  • Volume Avg (30-Day) 1,018
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 26,397
  • Open Int (30-Day) 22,894

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.88
  • Number of Estimates 5
  • High Estimate 0.93
  • Low Estimate 0.85
  • Prior Year 0.89
  • Growth Rate Est. (year over year) -1.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.92 +3.02%
on 02/06/25
Period Open: 63.12
66.24 -5.25%
on 01/30/25
-0.36 (-0.57%)
since 01/21/25
3-Month
55.68 +12.72%
on 01/10/25
Period Open: 60.76
66.24 -5.25%
on 01/30/25
+2.00 (+3.29%)
since 11/21/24
52-Week
50.01 +25.49%
on 06/11/24
Period Open: 54.22
66.24 -5.25%
on 01/30/25
+8.54 (+15.75%)
since 02/21/24

Most Recent Stories

More News
Are Wall Street Analysts Predicting Corteva Stock Will Climb or Sink?

Despite Corteva's underperformance relative to the S&P 500 Index over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

CTVA : 62.76 (-1.68%)
$SPX : 6,013.13 (-1.71%)
XLB : 88.07 (-1.83%)
Corteva, Inc.: Q4 Earnings Snapshot

Corteva, Inc.: Q4 Earnings Snapshot

CTVA : 62.76 (-1.68%)
How Trump’s AI Push Could Boost These 3 Agriculture Stocks

President Trump's push for technological developments in the agriculture sector could start to expand margins and EPS in these 3 stocks.

DE : 489.98 (-1.17%)
CTVA : 62.76 (-1.68%)
FMC : 38.25 (+0.16%)
Corteva Earnings Preview: What to Expect

Corteva is scheduled to release its fourth-quarter earnings next month, and analysts anticipate a significant triple-digit profit surge.

CTVA : 62.76 (-1.68%)
$SPX : 6,013.13 (-1.71%)
XLB : 88.07 (-1.83%)
2 Agriculture Stocks To Benefit From a Trump Presidency in 2025

President Trump's return to the White House could mean lower corporate taxes, less red tape, favorable trade deals to help the U.S. agriculture industry.

CTVA : 62.76 (-1.68%)
TSCO : 56.37 (-2.37%)
Is FMC Corporation Stock Underperforming the Dow?

FMC Corporation has underperformed the Dow over the past year, but analysts are moderately optimistic about the stock’s prospects.

CTVA : 62.76 (-1.68%)
$DOWI : 43,428.02 (-1.69%)
FMC : 38.25 (+0.16%)
Is Corteva Stock Underperforming the Nasdaq?

Despite Corteva’s recent underperformance relative to Nasdaq, Wall Street analysts remain moderately optimistic about the stock’s prospects.

CTVA : 62.76 (-1.68%)
$NASX : 19,524.01 (-2.20%)
FMC : 38.25 (+0.16%)
3 Hot Buyback Announcements That Will Drive Value in 2025

Share buybacks will boost these stocks' prices in 2025 and beyond. Robust cash flow and healthy balance sheets are two common factors.

CTVA : 62.76 (-1.68%)
ACM : 97.52 (-2.19%)
EOG : 133.08 (-1.91%)
S&P 500 and Dow Jones Post Record Highs in Holiday-Shortened Trade

The S&P 500 Index ($SPX ) (SPY ) Friday closed up +0.56%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.90%. Stocks settled moderately...

AMAT : 171.98 (-2.29%)
CTVA : 62.76 (-1.68%)
VYGR : 4.22 (-0.94%)
LVS : 44.02 (-2.11%)
WYNN : 90.76 (-2.90%)
ABNB : 146.07 (-5.95%)
$IUXX : 21,614.08 (-2.06%)
ASML : 737.21 (-0.79%)
ZNH25 : 109-220s (+0.47%)
FITB : 42.88 (-1.67%)
QCOM : 165.43 (-4.76%)
LRCX : 86.02 (-3.37%)
S&P 500 Posts a New Record High in a Holiday-Shortened Trading Session

The S&P 500 Index ($SPX ) (SPY ) today is up +0.45%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.38%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.70%. Stocks today are moderately higher,...

AMAT : 171.98 (-2.29%)
CTVA : 62.76 (-1.68%)
VYGR : 4.22 (-0.94%)
$IUXX : 21,614.08 (-2.06%)
ASML : 737.21 (-0.79%)
ZNH25 : 109-220s (+0.47%)
MSFT : 408.21 (-1.90%)
FITB : 42.88 (-1.67%)
S : 22.12 (-2.90%)
QCOM : 165.43 (-4.76%)
LRCX : 86.02 (-3.37%)
$DOWI : 43,428.02 (-1.69%)
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds

Citi noted the positive clinical data and the competitive pricing of Attruby at $225,000 per year, below Pfizer’s tafamidis.

BBIO : 36.85 (+0.12%)
VTI : 295.92 (-1.85%)
XBI : 91.70 (-1.10%)
BridgeBio Pharma Announces FDA Approval of Attruby™ to Treat ATTR-CM with Promising Cardiac Outcomes

BridgeBio's Attruby is FDA-approved for ATTR-CM, demonstrating significant cardiovascular benefits and providing lifetime free access for trial participants.Quiver AI SummaryBridgeBio Pharma, Inc. announced...

BBIO : 36.85 (+0.12%)
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

BBIO : 36.85 (+0.12%)
Insider Sale: Chief Executive Officer of $BBIO (BBIO) Sells 1,875 Shares

Neil Kumar, the Chief Executive Officer of $BBIO ($BBIO), sold 1,875 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.0% of...

BBIO : 36.85 (+0.12%)
Insider Sale: Secretary of $BBIO (BBIO) Sells 4,156 Shares

BRIAN C STEPHENSON, the Secretary of $BBIO ($BBIO), sold 4,156 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.2% of their...

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Announces Positive 18-Month Results for Infigratinib in Achondroplasia from PROPEL 2 Study

Infigratinib shows significant growth improvements in children with achondroplasia, with ongoing trials and FDA breakthrough designations.Quiver AI SummaryBridgeBio Pharma announced positive results from...

BBIO : 36.85 (+0.12%)
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BBIO : 36.85 (+0.12%)
BridgeBio Pharma: Q3 Earnings Snapshot

BridgeBio Pharma: Q3 Earnings Snapshot

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

BBIO : 36.85 (+0.12%)
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds

Citi noted the positive clinical data and the competitive pricing of Attruby at $225,000 per year, below Pfizer’s tafamidis.

BBIO : 36.85 (+0.12%)
VTI : 295.92 (-1.85%)
XBI : 91.70 (-1.10%)
BridgeBio Pharma Announces FDA Approval of Attruby™ to Treat ATTR-CM with Promising Cardiac Outcomes

BridgeBio's Attruby is FDA-approved for ATTR-CM, demonstrating significant cardiovascular benefits and providing lifetime free access for trial participants.Quiver AI SummaryBridgeBio Pharma, Inc. announced...

BBIO : 36.85 (+0.12%)
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

BBIO : 36.85 (+0.12%)
Insider Sale: Chief Executive Officer of $BBIO (BBIO) Sells 1,875 Shares

Neil Kumar, the Chief Executive Officer of $BBIO ($BBIO), sold 1,875 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.0% of...

BBIO : 36.85 (+0.12%)
Insider Sale: Secretary of $BBIO (BBIO) Sells 4,156 Shares

BRIAN C STEPHENSON, the Secretary of $BBIO ($BBIO), sold 4,156 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.2% of their...

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Announces Positive 18-Month Results for Infigratinib in Achondroplasia from PROPEL 2 Study

Infigratinib shows significant growth improvements in children with achondroplasia, with ongoing trials and FDA breakthrough designations.Quiver AI SummaryBridgeBio Pharma announced positive results from...

BBIO : 36.85 (+0.12%)
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BBIO : 36.85 (+0.12%)
BridgeBio Pharma: Q3 Earnings Snapshot

BridgeBio Pharma: Q3 Earnings Snapshot

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

BBIO : 36.85 (+0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corteva, Inc. provides agriculture products. The company develops and supplies germplasm and traits in corn, soybean and sunflower seed markets. It also supplies products to the agricultural input industry which protect against weeds, insects and other pests, and diseases as well as to enhance crop health....

See More

Key Turning Points

3rd Resistance Point 64.68
2nd Resistance Point 64.20
1st Resistance Point 63.48
Last Price 62.76
1st Support Level 62.29
2nd Support Level 61.81
3rd Support Level 61.09

See More

52-Week High 66.24
Last Price 62.76
Fibonacci 61.8% 60.04
Fibonacci 50% 58.13
Fibonacci 38.2% 56.21
52-Week Low 50.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements